| 영문 | endocrine gland | 한글 | 내분비샘 |
|---|---|---|---|
| 설명 | 신체의 내부로 분비가 되어서 다른 세포의 기능이나 활성의 변화를 일으키는 물질인 호르몬을 분비하는 곳을 이르는 말이다. 대표적인 내분비샘은 갑상샘, 부갑상샘, 부신, 이자, 뇌하수체, 난소, 고환, 솔방울샘, 가슴샘 등이다. 마지막에 나오는 2개의 기관은 내분비 기능을 하는 것으로 생각이 되지만 확실히 그것이 무슨 기능을 하는 지에 대해선 아직까지 정확하게 밝혀지지 않고 있다.  |
||
| 영문 | pancreatic duct | 한글 | 이자관, 췌장관 |
|---|---|---|---|
| 설명 | 이자에서 이자액을 분비하도록 샘창자로 이어진 관. 이자관은 샘창자의 중간부에서 온쓸개관과 같이 개구한다. |
||
| 영문 | muscle cell(=muscle fiber) | 한글 | 근육세포 |
|---|---|---|---|
| 설명 | 근육은 수의근(의식에 의해서 조절이 가능한 근육: 예를 들어 다리, 팔, 얼굴근육 등)과 불수의근(의식과 무관하게 조절하지 않아도 움직이는 근육: 예를 들어 심장근, 소화기관에 분포하는 근육 등)으로 나누어지며, 근육세포의 모양은 다음과 같다(수의근, 불수의근 외에 심장에 있는 심장근은 불수의근에 해당하지만 그 모양은 수의근과 같아 따로 분류한다).  |
||
| 영문 | white blood cell(WBC), leukocyte | 한글 | 백혈구 |
|---|---|---|---|
| 설명 | 혈액내에 골수구계세포와 림프계세포, 단핵구계세포를 모두 통틀어 말한다. 백혈구의 증가가 있으면 대개 감염이 있거나, 혹은 탈수현상이 있음을 의미한다. 또한 지나친 백혈구수의 감소는 인체내 면역기능이 떨어져 있음을 의미하며, 다른 질병에 의해 나타나는 이차적인 현상이 아닌지 꼭 진단을 받아보아야 한다. |
||
| 영문 | mast cell | 한글 | 비만 세포 |
|---|---|---|---|
| 설명 | 동물의 결합 조직 가운데 널리 분포하는 세포. 결합조직과 점막조직 내에 있는 호염기성 색소로 이염색성(metachromasia)을 나타내는 과립을 가진 방추형의 세포에 작은 둥근 핵을 가진다. 비만세포의 표면에는 IgE에 대한 수용체가 존재하며, 수용체에 결합한 IgE 분자들끼리 다가의 항원에 의해 서로 연결되면 비만세포 과립탈출 반응이 일어나, 히스타민, 세로토닌, 헤파린 등의 화학전달 물질이 방출되어, 즉시형 알레르기 반응 등의 증상을 일으킨다. 피부, 장막, 혈관 주위, 점막 주변에 있다. |
||
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
|---|---|
| EC | effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme... |
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
| EPT | Endocrine pancreatic tumors |
|---|---|
| PET | Pancreatic endocrine tumors |
| EO | Endocrine Ophthalmopathy |
| EACs | Endocrine active compounds |
| EDC | Endocrine disrupting chemicals |
| pancreatic acinar cell | <pathology> Cells of the pancreas that secrete digestive enzymes, the archetypal secretory cell upon which much of the early work on the sequence of events in the secretory process was done. (18 Nov 1997) |
|---|---|
| pancreatic isleT-cell tumours | <radiology> Insulinoma (beta-cell), usually solitary, 85% benign, gastrinoma, small, slow-growing, multiple, 60% malignant, Zollinger-Ellison syndrome: mult. Intractable ulcers, VIPoma, vasoactive intestinal peptide (VIP), WDHA syndrome: watery diarrhoea, hypokalaemia, achlorhydria, Verner-Morrison syndrome, glucagonoma, hyperglycaemia, migratory necrolytic erythema APUDomas, associated with MEN-1 (12 Dec 1998) |
| bone diseases, endocrine | Diseases of the bones related to hyperfunction or hypofunction of the endocrine glands. (12 Dec 1998) |
| multiple endocrine adenomatosis | The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance. Synonym: multiple endocrine adenomatosis. (05 Mar 2000) |
| multiple endocrine deficiency syndrome | <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis. Synonym: multiple glandular deficiency syndrome. (05 Mar 2000) |
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
| multiple endocrine neoplasia type 1 | A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients. (12 Dec 1998) |
| multiple endocrine neoplasia type 2 | <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. (27 Sep 1997) |
| multiple endocrine neoplasia type 2a | A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands. (12 Dec 1998) |
| multiple endocrine neoplasia type 2b | A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas. (12 Dec 1998) |
| neoplastic endocrine-like syndromes | Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm. (12 Dec 1998) |
| diagnostic techniques, endocrine | Methods and procedures for the diagnosis of diseases or dysfunction of the endocrine glands or demonstration of their physiological processes. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|